Advances in Therapy, volume 39, issue 1, pages 430-440

May Previous Hepatitis B Virus Infection Be Involved in Etiology and Pathogenesis of Autoimmune Liver Diseases?

Batskikh Sergey ¹

Morozov Sergey ²

Vinnitskaya Elena ¹

Sbikina Evgeniya ¹

Borunova Zanna ¹

Dorofeev Alexey ¹

Sandler Yulia ¹

Saliev Kirill ¹

Kostyushev Dmitry ^{3, 4}

Brezgin Sergey ^{3, 4}

Kostyusheva Anastasiya ³

Chulanov Vladimir ^{3, 4, 5}

Hide authors affiliations Show authors affiliations: 5 affiliations

Moscow Clinical Scientific Center n.a. A.S. Loginov, Moscow, Russia |

Department Gastroenterology, Hepatology and Nutrition, Federal Research Center of Nutrition and Biotechnology, Moscow, Russia |

National Medical Research Center of Tuberculosis and Infectious Diseases, Ministry of Health, Moscow, Russia |

⁴

Division of Biotechnology, Scientific Center for Genetics and Life Sciences, Sirius University of Science and Technology, Sochi, Russia |

⁵

Department of Infectious Diseases, Sechenov First Moscow State Medical University, Moscow, Russia |

Publication type: Journal Article

Publication date: 2021-11-11

Springer Nature

Journal: Advances in Therapy

Quartile SCImago

Quartile WOS

Impact factor: 3.8

ISSN: 0741238X, 18658652

DOI: 10.1007/s12325-021-01983-5

Copy DOI

General Medicine

Pharmacology (medical)

Abstract

Introduction Viral infections, especially with hepatotropic viruses, may trigger autoimmune liver diseases (AILDs) and deteriorate their course. However, association of previous hepatitis B virus (HBV) infection (presence of anti-HBc with or without anti-HBs or HBV DNA in serum) with AILDs is poorly studied so far. The aim of the study was to assess the prevalence of previous hepatitis B virus infection markers and its clinical significance in patients with autoimmune liver diseases. Methods The study was based on the data obtained from 234 consecutive HBsAg-negative patients with AILDs [81 with autoimmune hepatitis (AIH), 122 with primary biliary cholangitis (PBC) and 31 with primary sclerosing cholangitis (PSC)] and 131 subjects of the control group without liver diseases. Blood samples of the enrolled patients were tested for anti-HBc and HBV DNA. Samples of liver tissue were examined by standard morphologic protocol and, in anti-HBc positive subjects, for HBV DNA. We assessed estimated risks of AILDs according to anti-HBc positivity and association of anti-HBc positivity with stage of liver fibrosis. Results Anti-HBc was detected in 14.5% participants in the control group vs 26.1% ( p = 0.016) in patients with AILDs (including 27.1% subjects with PBC ( p = 0.021 vs control group), in 29% of PSC and 23.5% in AIH. HBV DNA was detected in three patients with PBC and in one with AIH. Positive anti-HBc test result was associated with higher risk of AILDs—odds ratio (OR) = 2.078 [95% confidence interval (CI) 1.179–3.665], especially in PBC: OR (95% CI) 2.186 (1.165–4.101). Odds of advanced stage of liver fibrosis (F3–F4 by METAVIR) in anti-HBc-positive subjects with PBC were also higher compared to those who had no previous HBV infection: OR (95% CI) 2.614 (1.153–5.926). Conclusions Significant proportions of patients with AILDs are anti-HBc positive, and some of them have OBI. Among patients with AILDs, anti-HBc-positivity is most widespread in the PBC group and in subjects with advanced stage of liver fibrosis. Our data may support the idea of an important role of previous HBV infection in the etiology and pathogenesis of AILDs (namely PBC).

By date By citations

Citations by journals

	1
Frontiers in Immunology	Frontiers in Immunology, 1, 50% Frontiers in Immunology 1 publication, 50%
GE Portuguese Journal of Gastroenterology	GE Portuguese Journal of Gastroenterology, 1, 50% GE Portuguese Journal of Gastroenterology 1 publication, 50%
	1

Citations by publishers

	1
Frontiers Media S.A.	Frontiers Media S.A., 1, 50% Frontiers Media S.A. 1 publication, 50%
Elsevier	Elsevier, 1, 50% Elsevier 1 publication, 50%
	1

We do not take into account publications that without a DOI.
Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
Statistics recalculated weekly.

{"yearsCitations":{"type":"bar","data":{"show":true,"labels":[2023],"ids":[0],"codes":[0],"imageUrls":[""],"datasets":[{"label":"Citations number","data":[2],"backgroundColor":["#3B82F6"],"percentage":["100"],"barThickness":null}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"journals":{"type":"bar","data":{"show":true,"labels":["Frontiers in Immunology","GE Portuguese Journal of Gastroenterology"],"ids":[1699,20816],"codes":[0,0],"imageUrls":["\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp"],"datasets":[{"label":"","data":[1,1],"backgroundColor":["#3B82F6","#3B82F6"],"percentage":[50,50],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Journals","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"publishers":{"type":"bar","data":{"show":true,"labels":["Frontiers Media S.A.","Elsevier"],"ids":[208,17],"codes":[0,0],"imageUrls":["\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp"],"datasets":[{"label":"","data":[1,1],"backgroundColor":["#3B82F6","#3B82F6"],"percentage":[50,50],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Publishers","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}}}

Metrics

Cite this

GOST |

Cite this

GOST Copy

Batskikh S. et al. May Previous Hepatitis B Virus Infection Be Involved in Etiology and Pathogenesis of Autoimmune Liver Diseases? // Advances in Therapy. 2021. Vol. 39. No. 1. pp. 430-440.

GOST all authors (up to 50) Copy

Batskikh S., Morozov S., Vinnitskaya E., Sbikina E., Borunova Z., Dorofeev A., Sandler Y., Saliev K., Kostyushev D., Brezgin S., Kostyusheva A., Chulanov V. May Previous Hepatitis B Virus Infection Be Involved in Etiology and Pathogenesis of Autoimmune Liver Diseases? // Advances in Therapy. 2021. Vol. 39. No. 1. pp. 430-440.

RIS |

Cite this